ARVN News and Press, Arvinas Inc. From 01/31/24

2024-01-31 17:03:58 ET Gainers: Nextracker  ( NXT ) +15% . Align Technology ( ALGN ) +11% . EZCORP ( EZPW ) +9% . Protagonist Therapeutics ( PTGX ) +8% . Cimpress ( CMPR ) +8% . Losers: MaxLinear ( MXL ) -8% ...

NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Jared Freedberg, J.D., has joined the company as General Counsel. “We are...

2024-01-06 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-19 13:36:10 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data ...

2023-12-15 16:20:04 ET Summary Positive interim data achieved by Arvinas, Inc. from phase 1b study using vepdegestrant for the treatment of patients with ER+/HER2- advanced or metastatic breast cancer patients respectively. Two ongoing phase 3 studies being advanced are using vepd...

2023-12-08 09:48:00 ET More on Arvinas Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data Arvinas stock jumps 30% amid positive data for breast cancer drug For further details see: Arvinas files to sell 16.39M shares of common stock for holders

2023-12-06 14:00:43 ET More on Arvinas Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Arvinas stock jumps 30% amid positive data for breast cancer drug Arvinas announces private placement to raise $350M Seeking Al...

2023-12-06 13:41:44 ET More on Arvinas Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Arvinas announces private placement to raise $350M Arvinas GAAP EPS of -$1.18 beats by $0.39, revenue of $34.6M misses by $5.45M ...

2023-12-06 12:41:58 ET More on Mid-day movers $ stocks. Altimmune: Don't Buy The GLP-1 Move-Up Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript Altimmune weight-loss drug performed...

NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc...